BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP
(Financial Post, 2025-11-06T11:06:40Z)